Patent ID: 11926671
Assignee: OSE IMMUNOTHERAPEUTICS
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC C

Claim 0:
1. A method of inhibiting inflammation associated with the interleukin-7 (IL-7) signaling pathway, the method comprising administering an effective amount of a composition comprising an anti-human CD127 agent to a patient in need thereof, wherein said anti-human CD127 agent comprises
an antibody or an antigen-binding fragment thereof comprising:
an antibody light chain comprising or an antibody light chain variable domain consisting of a sequence selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12; and
an antibody heavy chain comprising or an antibody heavy chain variable domain consisting of the sequence set forth in SEQ ID NO: 7;
wherein said antibody or an antigen binding fragment thereof specifically binds to CD127.